The clinical significance of oestrogen receptor expression in breast ductal carcinoma in situ by Miligy, Islam M et al.
1 
The clinical significance of Oestrogen receptor expression in breast ductal carcinoma in 
situ  
 
Islam M Miligy1*, Michael S Toss1*, Sho Shiino1, Georgette Oni2, Binafsha M Syed3, Hazem 
Khout2, Quing Tan2, Andrew R Green1, R Douglas Macmillan2, John FR Robertson4, Emad A 
Rakha1 
 
1Division of Cancer and Stem Cells, School of Medicine, University of Nottingham 
Biodiscovery Institute, The University of Nottingham, UK. 2The Breast Institute, Nottingham 
City Hospital, Nottingham University Hospitals NHS Trust, 3Medical Research Centre, Liaquat 
University of Medical & Health Sciences, Jamshoro, Pakistan, 4Division of Graduate Entry 
Medicine, School of Medicine, University of Nottingham Royal Derby Hospital, Derby, UK.  




Dr. Michael Toss  
Department of Histopathology, Nottingham University Hospital NHS Trust,  
City Hospital Campus, Hucknall Road, Nottingham, NG5 1PB, UK 
Tel: (44) 0115-9691169, Fax: (44) 0115-9627768 
Email: msxms8@nottingham.ac.uk  
 
Key words: DCIS, Oestrogen Receptors, nuclear grade, tumour recurrence, endocrine 
therapy 





Background: Oestrogen receptor (ER) in invasive breast cancer (BC) predicts response to 
endocrine therapy (ET) and provides prognostic value. In this study, we investigated the 
value of ER expression in ductal carcinoma in situ (DCIS) in terms of outcome and the impact 
on ET decision.  
Methods: 643 pure DCIS, diagnosed at Nottingham University Hospitals, were assessed for 
ER. Clinicopathological data were correlated against ER status together with assessment of 
recurrence rate. 
Results: ER-positivity was observed in 74% (475/643) of cases. ER positivity was associated 
with clinicopathological variables of good prognosis; however, outcome analysis revealed 
that ER status was not associated with local recurrence. In the intermediate and high-grade 
ER-positive DCIS, 58% (11/19) and 63% (15/24) of the recurrences were invasive, 
respectively, comprising 7% and 6% of all ER-positive DCIS, respectively. Invasive recurrence 
in low-grade DCIS was infrequent (2%) and none of these patients died of BC. The ER status 
of the recurrent invasive tumours matched the primary DCIS ER status (94% in ipsilateral 
and 90% of contralateral recurrence).  
Conclusion: The strong correlation between DCIS and invasive recurrences ER status and the 
clinical impact of ET justify discussion of the use of ET in ER-positive DCIS treated by breast 
conserving surgery. The excellent outcome of low-grade DCIS, which was almost always ER-
positive, does not, in the opinion of authors, justify the use of risk reducing ET. Therefore, 










In countries with routine mammographic screening, one case of pure ductal carcinoma in 
situ (DCIS) is diagnosed for every four cases of breast cancer (BC) 1. The management of 
DCIS continues to be a challenge. Although DCIS is predominantly associated with a low risk 
of mortality 2,3, it is well documented that it could progress into invasive BC (IBC), with an 
associated increased mortality risk 4,5. Precise identification of the mortality risk has been 
difficult as most of the studies do not provide long term (i.e. >20 years) mortality data. For 
example, a woman in her 40s or 50s treated with breast conserving surgery (BCS) who 
subsequently died following DCIS would normally develop an initial local invasive 
recurrence, then subsequently metastatic disease before eventually dying of BC. 
Furthermore, in the last 20 years the average survival of patients with ER positive primary or 
metastatic BC have increased. In addition, the psychological impact of a recurrence, in-situ 
or invasive disease, must also not be underestimated. Currently, lack of a robust tool to 
identify low risk DCIS results in recommendation that all women with DCIS undergo 
treatment. Results of clinical trials that provide no active treatment to low risk DCIS are 
awaited 6,7 .  
The optimal clinical management for women with newly diagnosed DCIS is controversial, 
with variable patterns of practice 8-10. The standard management options for the treatment 
of DCIS in the UK currently are mastectomy or breast-conserving surgery (BCS) with or 
without postoperative whole breast radiotherapy (RT) 11. 
Approximately 70% of women with DCIS will be treated with BCS followed by RT, because of 
its proven efficacy to reduce local recurrence (LR) risk 12-14. RT may be omitted for women at 
low risk of recurrence, however clinical and pathological features have not reliably identified 
patients at low risk of LR following BCS alone, leading to variability in treatment and 
outcomes of women with DCIS 15.  
Data on adjuvant endocrine therapy (ET) in DCIS continues to evolve debate. Its use has 
become more common in the United States, with approximately 60% of all DCIS cases 
having BCS receiving it in recent years 16. Adjuvant ET for hormone receptor–positive DCIS 
tumours, with Tamoxifen or aromatase inhibitors (e.g. Anastrozole), may improve local 
control in hormone-responsive disease 12,17-20 and reduce the risk of BC recurrence but 
survival benefit is unproven 4,12. Data on outcome by Oestrogen receptor (ER) status of the 
DCIS is absent in most randomised trials. However, a sub-study of 732/1799 (41%) of 
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patients in the NSABP B-24 trial reported that Tamoxifen significantly decreased BC 
recurrence in ER positive but not ER-negative DCIS 21. 
The National Institute for Health and Care Excellence (NICE) has updated the 
recommendations for adjuvant ET for DCIS to offer it after BCS for women with ER-positive 
DCIS if RT is recommended but not received; and to consider ET after BCS for women with 
ER-positive DCIS if RT is not recommended 22. The American Society of Clinical 
Oncology/College of American Pathologists also recommend testing of DCIS for ER to 
determine the potential benefit of ET to reduce risk of future BC 23. Although the concept of 
ET for ER-positive DCIS patients who require RT, but cannot or choose not to receive it, is 
obvious as these patients are usually at high risk of disease progression and/or recurrence, 
this is currently a relatively small group. In reality, most women suitable to receive ET for 
DCIS also receive RT and/or are low risk 16. Moreover, clinical application of these 
recommendations means that ER testing would be necessary for all DCIS in order to be 
considered for management decision. However, DCIS is not routinely stained with ER and 
the impact of ET on the outcome of DCIS, and whether this impact is limited to ER-positive 
DCIS, remains to be defined. Furthermore, routine measurement of ER would increase the 
burden on the pathology service. The effect of implementation of such recommendation on 
clinical practice and the effect on overall patient mortality and morbidity should be 
investigated. 
In this study, we used a large retrospective cohort of DCIS treated in a single institution to 
address the outcome of ER-positive DCIS, especially invasive recurrence to consider the 
utility of routine ER testing in these patients. We have also reviewed the randomised studies 
reporting on adjuvant ET and clinical outcomes of DCIS.  
 
Patients and Methods 
A pure DCIS cohort (n=1249) diagnosed at the Nottingham University Hospitals NHS Trust 
over a 30-year period (1990-2017) with at least 5 years follow-up time was identified. DCIS 
associated with invasive or micro-invasive carcinomas was excluded. All demographic, 
clinical, pathological, and outcome data were retrieved from patients’ records. Nuclear 
grade was assessed using the previously published criteria 24-26. In the current study glass 
slides from all cases were reviewed histologically by an observer and graded according to 
World Health Organisation (WHO) criteria of breast tumours classification. Grade was 
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compared with the originally reported grade and conflicted cases were reviewed by a 
consultant pathologist. Cases with more than one grade were reported and the higher grade 
was considered in the final analysis. Management details including the operation type (BCS 
or mastectomy), and RT data were collected. Over the period of the study, the management 
of DCIS showed significant changes with an increase in rate of BCS over mastectomy, and 
more frequent use of local RT as previously described 27. ER status was not routinely 
assessed in DCIS unless indicated for diagnostic purposes and was not used to guide further 
management. Ten- and fifteen-year ipsilateral BC tumour recurrence (BCTR) was defined as 
any event of ipsilateral local tumour recurrence (either as DCIS (DCIS-BCTR) or invasive 
disease (I-BCTR)) occurring after 6 months from the first DCIS surgery and up to 120 and 180 
months respectively. Contralateral BC (CBC) was assessed and defined as any contralateral 
breast event, either DCIS or IBC, identified after the primary diagnosis of DCIS. BC specific 
survival was defined as the time from the primary diagnosis of DCIS to death from BC. 
Patients were censored at the last time they were seen alive, died of other caused or the 
time they were lost to follow-up. ER status of the invasive recurrences either ipsilateral or 
contralateral was available as part of the routine management of patients. 
In this study, ER status was assessed retrospectively on tissue microarray (TMA) sections of 
DCIS sample using immunohistochemistry for research purposes as previously described  28. 
Briefly, 4µm sections were stained on the diagnostically valid Ventana Benchmark® ULTRA 
system (Tucson, Arizona, USA) using Ventana anti-ER (SP1) Rabbit Monoclonal Primary 
Antibody as per the recommended protocol. Sections were deparaffinised and antigen 
retrieval was performed with Cell Conditioner 1 (CC1) for 60 min. The primary antibody was 
applied for 16 minutes at 37°C followed by the OptiView HQ Linker for 8 minutes and the 
OptiView HRP Multimer for 8 minutes. Counter-staining was performed with Mayer’s 
haematoxylin. Positive control cores were added to each TMA section. Only nuclear staining 
of DCIS cells was scored. ER positivity was considered when ൒1% of DCIS cells showed 
nuclear staining 23. The final number of cases that were suitable for assessment for ER was 
643/1249 (51%) cases, according to the availability of tumour tissue and informative cores 
in the TMA blocks. Data on Progesterone receptor (PR) and HER2 status based on 






Statistical analyses were performed using SPSS v26 (Chicago, IL, USA) for Windows. 
Association between ER status and clinicopathological parameters was evaluated using Chi-
squared test ER associated risk with ipsilateral and contralateral recurrence was evaluated 
individually as well as the overall risk combining both ipsilateral and contralateral events. 
Univariate survival rates were determined using the Kaplan–Meier method and compared 
by the log-rank test. A multivariate Cox regression hazards regression model was used to 
adjust confounding factors.  All tests were 2-tailed and a p value of less than 0.05 was 




A total of 475/643 (74%) DCIS cases showed positive expression of ER defined as ൒1% of 
tumour cells showing nuclear positivity. In this study, only 4 cases (0.8%) showed ER 
positivity in 1-10% of tumour cells. There was a trend towards an increase in ER positivity 
over the period of the study (Figure 1). This was accompanied by increase rate of screen 
detected DCIS and lower rate of high-grade DCIS (Figure 1). High nuclear grade was 
observed in 60% of cases (388/643), while comedo necrosis was present in approximately 
two thirds of cases (64%). 300 (47%) patients were treated by BCS, while one third of them 
received RT (100/300). Over the period of the study, there was an increase in the rate of 
BCS as a primary surgical choice and rate of offering RT (Figure 1).  
Association between ER and other clinicopathological factors  
ER positivity was associated with features of good prognosis including smaller tumour size 
(<40mm), low nuclear grade, absence of comedo necrosis, positive PR status and lack of 
HER2 overexpression (all p<0.0001). ER-positive DCIS patients were more likely to be 
treated with BCS (p<0.0001), without adjuvant RT (p=0.039) compared to ER-negative cases 
(p<0.0001). Table 1 summarises the correlations between ER expression and other 





Ipsilateral local recurrence and ER status  
The number of cases who developed ipsilateral local recurrence (ILR) over a period of 10-
year follow-up was 61 (9%), of which 35 patients (57% of recurred cases and 5% of the 
overall cohort) developed invasive ILR. 56 cases (92% of all recurrences) recurred after BCS 
(with or without RT) (56/300, 19%) and only five cases (8% of all recurrences) occurred after 
mastectomy (5/343, 1%). Within the BCS treated group, 55% of recurrences (31/56) were 
invasive recurrence. No statistically significant difference was observed between ER status 
and ILR in patients treated with BCS at 10-year (p=0.511) and at 15-year follow up 
(p=0.473); (Figure 2). Similar results were showed when the analysis was carried out the 
whole cohort regardless the surgical management (Supplementary Figure 1) and in 
multivariate analysis with other confounders factors including age at diagnosis, tumour size, 
grade and RT (Supplementary Table 1). In ER positive cohort, recurrence was mainly 
associated with nuclear grade and RT (Table 2).  RT improved the outcome in the whole 
cohort and in ER-positive DCIS (p=0.039 and p=0.040, respectively). 
80% of patients who developed invasive ILR within 10 years, were initially treated for ER-
positive DCIS (28/35). Data on the ER status of the invasive ILR (n=30) showed that 94% of 
these tumours had the same ER status as the primary DCIS. 22 out of 23 ER-positive DCIS 
patients developed ER-positive invasive ILR (96%), whereas 6 out of 7 ER-negative DCIS 
patients developed ER-negative invasive carcinoma (86%). The discrepant ER-positive case 
was a patient who had intermediate and high-grade DCIS who subsequently developed ER-
negative invasive disease, which was grade 3 ductal carcinoma of no special type (NST) 
associated with high grade DCIS (which was most likely a new primary). The discrepant ER-
negative case was high grade DCIS with a triple negative phenotype whereas the 
subsequent tumour was ER-positive invasive lobular carcinoma, which could be 
representative of a new primary rather than being a true recurrence from the primary DCIS 
tumour.  
Outcome of ER-positive DCIS based on nuclear grade 
ER-positivity was more frequent in low and intermediate grade DCIS than high grade. 44 
patients who had ER-positive DCIS and were treated with BCS developed ILR within 10 
years. 59% (26/44) of these were invasive disease, (11 cases followed intermediate grade 
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DCIS and 13 cases followed high grade DCIS). Two low-grade ER-positive DCIS recurred as 
invasive disease (2% of low-grade DCIS), and both recurrences were low grade ER-positive 
invasive carcinoma associated with low grade DCIS. Both patients were alive at the end of 
follow up; the 10-year survival rate in this group was 100%. Table 3 summarises the 
percentage of ER-positive cases within the different grades of the DCIS cohort.  
The invasive recurrence rate in the ER-positive intermediate and high-grade DCIS groups 
were 7% and 6% respectively. The ER status of the invasive recurrence was 100% identical 
for the intermediate grade group while 92% of invasive recurrences occurred after primary 
diagnosis of high-grade ER-positive DCIS showed similar ER positivity.   
Interestingly, the figures of the overall recurrence rate up to the end of follow-up period for 
each nuclear grade were comparable with the 10-year recurrence rate in terms of ER 
positive recurrences (Table 3). 
Contralateral breast cancer and ER status  
Contralateral BC (CBC) was identified in 55/643 cases (9%); of which 37 cases were invasive 
disease (representing 6% of the overall cases and 67% of the contralateral events). In 
patients initially treated for ER-positive DCIS, 30 cases had invasive CBC. The primary DCIS in 
those cases were high grade in 14 patients (47%), intermediate grade in 11 (34%) and low 
grade in 5 cases (17%). 90% (27/30) of the contralateral invasive disease cases were ER-
positive. The three discrepant cases that developed ER-negative contralateral invasive 
disease (high-grade NST type) initially presented with high-grade ER-positive DCIS.   
The association between overall risk of developing a recurrent IBC event either ipsilateral 
or contralateral after primary diagnosis of DCIS and ER status 
The 10-year risk of developing a recurrence episode either in the ipsilateral or contralateral 
breast was 17% (109/643), of which 69 events were invasive disease (11% of all cohort and 
63% of all event). Within those 69 cases, the primary DCIS was ER-positive in 55 cases (80%). 
Most of the recurrent events after diagnosis of ER-positive DCIS showed positive ER 
expression, with few events recurring as ER-negative disease (Table 4).   
Overall survival  
The ten and twenty-year overall BC specific death rate was 0.9% (6/643) and 1.3% (9/643), 
respectively. Those patients had median age of 66 years, initially presented high grade DCIS, 
with comedo necrosis and half of them were treated with BCS. The ER status was positive in 
6 cases (67%). The recurrent episode was invasive carcinoma for all cases prior to distant 
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metastasis and death. Thus, the overall death rate after primary diagnosis of ER-positive 
DCIS was less than 0.5% and 0.7% within 10 years and twenty years of the primary diagnosis 
of DCIS respectively. In addition, none of the patients initially presented with low grade DCIS 
died during the 20- year period of the study follow-up.   
 
DISCUSSION 
Optimal treatment of DCIS is still a controversial issue. Debate continues regarding potential 
overtreatment of DCIS; whether surgical excision is required for all cases, and the question 
as to whether adjuvant therapy, RT and/or ET can be avoided for low-risk subgroups 16. 
Some multi-institutional randomised trials are underway comparing active monitoring with 
standard treatment for DCIS 7,30. The LORIS (low-risk DCIS) trial, which started in 2014, is a 
randomised, non-inferiority trial of comparing surgery versus active surveillance in low-risk 
DCIS patients. Patients with low- or intermediate-grade DCIS are randomised to either 
surgery or active surveillance with no hormonal treatment. The Comparison of Operative 
versus Medical Endocrine Therapy for Low-Risk DCIS (COMET) trial is currently on-going and 
randomises low- and intermediate-grade ER-positive and HER2-negative DCIS to either 
standard management versus active surveillance. ET use is encouraged in the active 
monitoring arm. The European Organisation for Research and Treatment of Cancer (EORTC)-
sponsored LOw Risk DCIS (LORD) trial, is due to open, and this will randomise patients with 
low-grade DCIS to conventional treatment versus an active monitoring strategy. The 
principle objective of these trials is to avoid over treatment of low risk DCIS and to provide 
evidence that active surveillance is a management option for these patients.   
In this study, there was a steady increase in the proportion of ER positive DCIS over the 
time, which was correlated with lower rate of HER2 positivity and higher rate of breast 
conservation as the primary option of DCIS management as illustrated in Figure 1. This 
constellation of observed features could be a reflection of the presence of a well-
established screen programme throughout the period of the study that led to increasing 
detection of DCIS of small size and low grade and decease rate of high-risk DCIS (based on 
tumour grade, size and patient age at diagnosis) 31,32. Another possibility for higher rate of 
ER positivity throughout the time of the study that cannot be entirely excluded is that the 
tissue specimens were fresher, and the integrity of the tissue was better. However, the 
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Nottingham cohorts of breast cancer including DCIS follow a standardised protocol of 
specimen fixation and processing in addition to tissue block storage. Based on our 
experience with hundreds of biomarkers tested using IHC in the invasive and the in situ 
diseases, no significant trend in the rate of positivity was observed between different time 
points and the rate of positivity of different markers is mainly related to tumour and tissue 
characteristics rather than the age of the specimen or the time period of storage. Using 
Benchmark IHC auto-stainer and ER antibody, which is used in routine clinical workflow, to 
stain ER in this study reduce the possible technical errors and false staining results.   
These findings were addressed in our previous work using on the same cohort which where 
we showed lower rates of high risk DCIS over the time which was reflected by higher rate of 
BCS as a primary surgical management, lower rate of second operation 27 and decrease the 
proportion of HER2 positive DCIS over time 29. Moreover, the protocol for management of 
DCIS in routine practice changed over the time. Overall, in our series, 41% of BCS treated 
patients were offered post-operative RT. However, prior to 2008, it was a common practice 
in our centre not to offer RT to DCIS patients with clear pathological margins 10 mm or 
more. Following evidence and that showed that closer margins are acceptable, the margin 
width was reduced, and this was followed by increasing use of RT in BCS treated DCIS 
patients. Selective RT regimen was also introduced. RT was then recommended after BCS to 
those with high grade DCIS, women younger than 50 years old and lesions more than 
30mm, regardless of tumour grade, following a multidisciplinary team discussion even if the 
margin is clear 27. In this study, there were 6 cases of low-grade DCIS which showed ER 
expression negativity. Although this is an unusual observation, assessment of ER on TMA 
sections which might underestimate the heterogeneity of ER expression in terms of 
morphological type and grade within the whole tumour. Interestingly, the PR status of these 
cases was negative. From our clinical experience, we came across few cases of low nuclear 
grade DCIS that are ER negative in routine practice and the diagnosis is usually based on the 
cytonuclear and architecture features which were sufficient for the diagnosis of DCIS and 
did not fit any other entity included in the differential diagnosis. In addition, we diagnosed 
occasional cases of ER negative low nuclear grade apocrine type DCIS that show typical 
architecture pattern of DCIS. Despite the low nuclear grade features, the cytoplasm was 
abundant and eosinophilic mimicking apocrine type cells. In our cohort, some of the low-
grade DCIS that showed ER negativity had such apocrine morphology (Supplementary Figure 
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3). This indicates that ER negative low nuclear grade DCIS exists but are extremely rare 
however, the false negative ER expression resulting from the use of TMA in this study may 
have exaggerated this phenomenon. 
Although prognosis following a diagnosis of DCIS is excellent, the goal of ET is to reduce 
invasive recurrence, which occurs in up to half of the recurrent cases 16. Few clinical trials 
reported in the literature have evaluated the response of DCIS patients to ET following BCS 
and RT with or without comment on ER status, either comparing Tamoxifen versus placebo 
20,33 or comparing the difference of clinical benefit between Tamoxifen and Anastrozole 18,19. 
For each study, updated results were published afterwards and were included in 
Supplementary Table 2.  
In the National Surgical Adjuvant Breast and Bowel Project (NSABP) B-24 trial, all women 
with DCIS (n=1804) received RT before being randomly assigned to ET or placebo. After a 
median follow-up of 6 years, a significant 37% reduction in BC recurrence was observed with 
ET compared with placebo. BC events were also lower in the Tamoxifen treated group 
(6.0%) compared to the placebo arm (9.3%) in the ipsilateral breast (p=0·0009). The 
cumulative incidence of all IBC events in the ET group was 2.1% in the ipsilateral breast at 5 
years compared to 4.2% in the placebo arm 20.  
In a retrospective evaluation of ER and PR in 732/1804 patients from the B-24 trial, 449 
tumours had ER and PR measured at a central lab while the remaining 283 tumours had 
results from the enrolling institutions. 76% of DCIS was ER-positive, 24% were ER-negative. 
Benefit of ET by receptor status at 10 years was evaluated with overall median follow-up of 
14.5 years. Patients with ER-positive DCIS treated with ET (versus placebo) showed 
significant 51% reduction in subsequent any BC (ipsilateral and contralateral, invasive and 
non-invasive) at 10 years (HR=0.5; p=0.001). No significant benefit was observed in ER-
negative DCIS 21. They concluded that the use of adjuvant ET (Tamoxifen) offered an 
additional therapeutic option for patients with ER-positive DCIS 21. 
In the UK/ANZ DCIS trial, 1578 women with DCIS were randomly assigned to receive 
Tamoxifen with or without RT. After a median of 13 years of follow-up, Tamoxifen 
significantly reduced all new BC events by 29%, with a significant impact on ipsilateral DCIS 
recurrence and contralateral tumours, but no effect on ipsilateral invasive recurrence 12,33. 
ER was not an entry criterion and there was no analysis of the invasive recurrence by ER 
status of the initial DCIS.  
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Overall, the evidence from the former studies is that ET significantly decreases BC 
recurrence. Based on the sub-study on B-24 this would appear to be limited to ER-positive 
DCIS and not ER-negative DCIS. These findings would be supported by the BC prevention 
studies of Tamoxifen 34 and aromatase inhibitors 35,36 versus placebo, which have reported a 
significant reduction in ER-positive BC (both invasive and DCIS) but no significant reduction 
in ER-negative BC. 
In an observational study of a prospective artificially randomised cohort 37, low dose 
Tamoxifen showed 30% reduction of any type of recurrence in women with high risk ER-
positive DCIS (p=0.005). However, when ipsilateral invasive recurrence only was considered 
the difference was not significant (p=0.21). 
However, it is noted that these studies were not large enough nor were they designed to 
assess survival benefit. Importantly, the NSABP B-24 and UK/ANZ studies were on patients 
unselected by ER status. Although the subset of cases with known ER status in the NSABP-24 
and showed that adjuvant Tamoxifen significantly reduced subsequent ipsilateral BC only in 
patients with ER-positive DCIS after standard treatment with lumpectomy and RT and not 
ER negative, there was no association, in subgroup analysis, with ipsilateral invasive 
recurrence (p=0.1) or contralateral invasive recurrence (p=0.06), which are more important 
than the overall recurrence rate. Similar results were shown in NSABP B-35 where no 
obvious reduction of invasive recurrence was shown.  It is noteworthy that neither of the 
randomised controlled trials considered DCIS grade as an inclusion criterion for patients. 
However, the current results showed that DCIS grade is more important than ER status to 
consider in prediction of recurrence risk after BCS for DCIS patients (Supplementary Figure 
2) independent of other confounding factors (Supplementary Table 1) . 
Therefore there remains confusion regarding treatment of DCIS with one trend toward 
avoiding surgical treatment (and subsequently no RT) and another trend to offer more ET 
therapy to DCIS patients and to make ER status assessment mandatory in all DCIS to allow 
clinicians to offer ET to ER-positive patients 22,23.  
Importantly, the studies which evaluated the benefit of ET therapy in DCIS considered both 
ipsilateral (likely a true recurrence but could be a new event) and contralateral events (a 
new event). Therefore, it was difficult to differentiate whether the benefits obtained by ET 
following the diagnosis of DCIS is related to treating the index DCIS itself to prevent its 
recurrence as invasive disease or if the use of ET in these cases was more prophylactic to 
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reduce the overall risk of invasive disease in patients with ER-positive disease. The former 
aims treat DCIS as an index lesion akin to adjuvant ET of invasive disease whereas the latter 
aims at treating DCIS as a marker of subsequent risk 38. The results of the current study 
support the fact that ER-status of the primary DCIS correlates strongly with the ER-status of 
recurrent invasive disease in the same or contralateral breast and therefore justify the use 
of ET in these patients. On the other hand, ER-negative DCIS is associated with development 
of ER-negative invasive disease, so ET is unlikely to influence the risk of invasive disease 
development. We also showed that RT in general and RT regardless of the ER status, offered 
to ER-positive DCIS cases have improved outcome after BCS. Therefore, the current results 
support NICE guidelines to provide ET for patients with high risk ER-positive DCIS when RT 
cannot be given for any reason 22. In ER negative DCIS, RT reduce the risk of recurrence from 
28% (9/32) in patients who did not receive RT, to 19% (5/26) in patients who receive post-
operative RT, however this difference was not statistically significance likely due to small 
number of ER negative cases included in the analysis.  
In the current study, our results showed that there is no significant association between ER 
status and the development of an ipsilateral breast event, either as DCIS or invasive 
recurrence. This was similar when we carried out the analysis on BCS treated patients only 
or when we included the whole cohort regardless the surgical management. We focused 
mainly on BCS group as they are the group of interest in NICE guidelines. the rate of 
recurrence after mastectomy was very low (1.2% recurrence rate which was ~6% of all 
recurrences in the study cohort). Patients’ treated with mastectomy usually receive no 
further therapy (neither RT nor ET) thus they are not included under the recommendation 
of NICE guidelines and. The current finding is similar to that of the sub-study of NSABP B-24 
21 and also of other studies 37,39, where the recurrence rates in the placebo group were 
similar for both ER-positive and ER-negative DCIS. We also showed that ER was not a 
contributing factor affecting the development of CBC in DCIS patients.  
It is important to rationalise the use of prophylactic or preventive therapy considering the 
side effects 40,41, cost and the magnitude of risk when planning such therapies; patients who 
are at high risk of disease development or those likely to develop high risk disease will 
derive the most benefit from such therapy.  The results in the current study showed that 
low grade DCIS treated with BCS, had excellent prognosis with 100% survival rate even in 
the occasional patients who developed invasive disease, which was low grade ER-positive 
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invasive carcinoma. In addition, all ER-positive DCIS that recurred as invasive disease and 
showed subsequent BC related mortality incident were of high-grade, and they were 
treated with BCS only. Therefore, we consider adjuvant ET for low risk DCIS is questionable 
as in view of the excellent outcome event in the recurrent cases. In RTOG 9804, there are so 
few events at the time of analysis that the data could not support or refute the role of ET in 
the treatment of low risk DCIS 42. Another important finding in this study is the difference 
between low-nuclear grade DCIS and the intermediate and high-nuclear grade DCIS group of 
patients regarding the development of invasive carcinoma risk and that the binary 
distinction of DCIS for risk stratification should be between low and intermediate / high-
nuclear grade group rather than between low/intermediate and high-nuclear grade groups 
of DCIS. 
The current study has some potential limitations. None of the patients included in this 
cohort were offered adjuvant ET. Management of DCIS was following local institutional 
protocols, and this was in line with the local and national UK guidelines present at the time 
of the study. The National Comprehensive Cancer Network (NCCN) and NICE guidelines for 
offering ET in DCIS were published in 2017 and 2019, respectively 22,43 which were not 
available during the period of the study. Second, the study was conducted on DCIS cases 
spanning a long time period with potential bias regarding the availability of tumour tissue 
for ER assessment. Thirdly, ER was evaluated on TMA sections which might underestimate 
the heterogeneity of ER expression within the whole tumour. The interobserver variability in 
DCIS grading is another potential limitation. Although DCIS grading similar to other 
biological features of differentiation is subjective and distinction between intermediate and 
high-grade DCIS is often challenging, diagnosis of low-grade DCIS is considered to be the 
easiest and more objective.  
CONCLUSIONS: There is a tendency for overtreatment of DCIS which can be by surgery 
and/or RT and/or ET. Although the impact of ET on the overall survival of DCIS patients is 
not demonstrated, ET reduces the risk of development of an invasive disease by up to 40%. 
Recommending ET to DCIS patients who do not receive RT can be justifiable however this 
should be based on ER status (positive) and grade (intermediate and high) of DCIS. ET 
appears to reduce the risk of invasive disease in general and not just limited to reducing the 
incidence of recurrence of the index DCIS and as such its use may contrast with the purpose 
of its use in IBC patients. The routine management of all DCIS including the low risk group 
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with ET does not appear to be justified by current data. There is an urgent need for 
molecular biomarkers and evidence-based guidelines to further refine the recurrence risk 
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Figure 1: The annual rates of the various clinicopathological parameters of the study cohort, 
over the period between 1987 and 2017. The graph shows a slightly increase in ER positivity 
rate over the time accompanied by a quite similar change in breast conserving surgery (BCS) 
rates. There was a steady increase of screen detected DCIS and radiotherapy rates over the 
time. There was a slightly lower rates of high-grade DCIS from the start of the study till end 
which was reflected on HER2 positivity rate. Low risk DCIS rate increased over time as well.  
 
*Radiotherapy rate for BCS treated patients only,  
** DCIS risk estimated based on tumour size, grade, and age at diagnosis)  
    

Figure 2: Kaplan-Meier curve shows the association between ER expression and ipsilateral 
local recurrence rate in patients treated with breast conservative surgery (Horizontal axis: 
local recurrence free interval in months, vertical axis: probability of recurrence). Number of 
cases at risk after 15 years becomes smaller for meaningful statistical analysis. 
































































































































































DCIS: Ductal carcinoma in situ, N: Number, X2: Chi square, p value in bold: significant. 
ER: Oestrogen receptor, BCS: Breast conserving surgery, PR: Progesterone Receptor. 
*Age and size: categorised according to the Van Nuys Prognostic Index (VNPI),  
+Management is according to the final operation 
**Radiotherapy status is for cases treated with BCS,  
***HER2 final status is achieved using combination of IHC and chromogenic in situ hybridisation (CISH). 
Table 2: Correlation between various clinicopathological factors and recurrence in ER 
positive DCIS treated with breast conserving surgery.  
 
Parameter 
ER Positive DCIS in BCS treated patients (n=242) 
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DCIS: Ductal carcinoma in situ, N: Number, X2: Chi square, p value in bold: significant. 
PR: Progesterone Receptor. 
*Age and size: categorised according to the Van Nuys Prognostic Index (VNPI),  
**HER2 final status is achieved using combination of IHC and chromogenic in situ hybridisation (CISH) 
Table 3: Oestrogen receptor status among the different DCIS grades and the corresponding recurrence rate  




10-year overall (DCIS 
and invasive) recurrence 
rate in the ER-positive 










(DCIS and invasive) 
recurrence rate in 
the ER-positive 










Low (n=88, 14%) 82 (94% of low 
grade) 
4 cases (5% of all low-
grade ER-positive cases) 
2 (2%) 2 (100%) 5 cases (6% of all 
low-grade ER-
positive cases) 







155 (94% of 
intermediate 
grade) 
19 (12% of all 
intermediate grade ER-
positive cases) 




20 (13% of all 
intermediate grade 
ER positive cases) 







238 (61% of 
high grade) 
24 (10% of all high-grade 
ER-positive cases) 
15 (6%) 11/12 cases 
with available 
ER data were 
ER-positive 
(92%)  
30 (13% of all high-
grade ER positive 
cases)  
20 (8%) 14/15 cases 
with available 




Table 4: Oestrogen receptor status of the primary DCIS and the subsequent invasive episodes either ipsilateral or 
contralateral 
ER status within the 
primary DCIS that had 
subsequent invasive 
episode (n=69; 10%) 
ER status within the invasive disease (ipsilateral and/or contralateral) 
Positive Negative Unknown  
Positive (n=55; 12%) 46 (92% of valid cases) 4 (8% of valid cases) 5 

























Supplementary Figure 1: Kaplan-Meier curve shows the association between ER 
expression and ipsilateral local recurrence rate in the whole cohort regardless the surgical 
treatment (Horizontal axis: local recurrence free interval in months, vertical axis: probability 
of recurrence).  
  
Patients at risk        
471         365          220          93          
167         117          76            39            
p value at 120 months =0.721 
p value at 180 months = 0.540 
2 
 
Supplementary Figure 2  
 
 
Supplementary Figure 2: Kaplan-Meier curve shows the association between DCIS grade 
and ipsilateral local recurrence (all recurrence in the upper curve and invasive recurrence in 
the lower curve). (Horizontal axis: local recurrence free interval in months, vertical axis: 




Supplementary Figure 3 
 
 
Supplementary Figure 3: Photomicrographic examples of low-grade DCIS that show 
negative expression of oestrogen receptor (ER); A) H&E stained section, B-D) 
immunohistochemistry stained sections showing negative ER expression. Note the apocrine 
changes (abundant esinophilic cytoplasm) and low-grade morphology.      
 
 
Supplementary Table 1: Multivariate analysis of various variables associated with DCIS 





95.0% CI for Exp(B) P value 
Lower Upper 
Patient age at diagnosis  1.5 1.3 1.8 0.008 
DCIS size 1.5 0.8 2.5 0.170 
DCIS Grade  1.5 1.1 2.2 0.027 
Radiotherapy 0.4 0.2 0.9 0.018 
Oestrogen receptor status 0.9 0.5 1.9 0.985 
Significant p values are in bold 
  
Supplementary Table 2: Clinical trials for the role of hormonal therapy in DCIS after 
breast conserving treatment  .
Study ER status as inclusion 
criterion  
Primary End points Outcome of the study 
Radiotherapy (RT) and 
Tamoxifen in women with 
completely excised ductal 
carcinoma in situ of the 
breast in the UK, Australia, 
and New Zealand: 
randomised controlled trial 
[30]. 
No prior knowledge of 
the hormone receptor 
status of the patients. 
To compare the efficacy of 
complete local excision alone 
with excision followed by RT to 
the residual ipsilateral breast, or 
excision followed by Tamoxifen 
for 5 years, or both, in reducing 
the incidence of subsequent 
ipsilateral invasive breast 
carcinoma in patients with DCIS. 
Ipsilateral invasive disease was not 
reduced by Tamoxifen, but recurrence 
of overall DCIS was decreased. RT 
reduced the incidence of ipsilateral 
invasive disease and ipsilateral DCIS, 
but there was no effect on the 
occurrence of contralateral disease. 
There was no evidence of interaction 
between RT and Tamoxifen. 
Tamoxifen in treatment of 
intraductal BC: National 
Surgical Adjuvant Breast and 
Bowel Project B-24 
randomised controlled trial 
[20]. 
No prior knowledge of 
the hormone receptor 
status of the patients. 
 
Occurrence of invasive or non-
invasive tumours in the 
ipsilateral or contralateral breast 
following Tamoxifen therapy. 
The effectiveness of Tamoxifen in 
treating DCIS without RT is speculative. 
The value of Tamoxifen used in 
combination with RT to lower the 
occurrence of invasive cancer could 
justify the suggestion that combined 
therapy replaces mastectomy for the 
treatment of DCIS patients in whom 
radiological findings are unlikely to be 
related to an invasive tumour 
Adjuvant Tamoxifen reduces 
subsequent BC in women 
with oestrogen receptor-
positive ductal carcinoma in 
situ: a study based on NSABP 
protocol B-24 [21]. 
ER and PR evaluation 
was carried out later 
for a subset of cases.  
Time to the occurrence of any BC 
as a first event ipsilateral or 
contralateral subsequent to the 
original diagnosis of DCIS. 
Adjuvant Tamoxifen significantly 
reduced subsequent ipsilateral BC only 
in patients with ER-positive DCIS after 
standard treatment with lumpectomy 
and RT. Tamoxifen reduced 
contralateral BC in patients with ER-
positive and -negative DCIS. No 
ipsilateral benefit was observed in ER-
negative disease. 
Primary results, NSABP B-
35/NRG Oncology: A clinical 




undergoing lumpectomy plus 
RT A randomized clinical trial 
[18]. 
ER or PR positive BC-free interval, the time from 
randomisation to any BC event 
including local, regional, or 
distant recurrence or 
contralateral disease, invasive or 
DCIS. 
There was no significant decrease in 




Tamoxifen for the prevention 
of locoregional and 
contralateral BC in 
postmenopausal women 
with locally excised ductal 
carcinoma in situ (IBIS-II 
DCIS): a double-blind, 
randomised controlled trial 
[19]. 
ER and PR positivity 
was determined as 
greater than or equal 
to 5% positive cells 
(equivalent of Quick- 
score of three or above 
and H-score of ten or 
above).  
The development of 
histologically confirmed BC, both 
invasive and new or recurrent 
DCIS.  
 
No clear efficacy differences were seen 
between the two treatments.  
BC=Breast cancer, RT=Radiotherapy 
